Final-Program-ATS-2023-AP.vp

TUESDAY • MAY 23

291

2:39 Geography and Suboptimal Inhaler Regimens After COPD Hospitalization/ A.K. Baldomero, Minneapolis, MN 2:51 Association Between Rural Residence and Quality of Care Delivery Among Veterans Following Chronic Obstructive Pulmonary Disease Exacerbation/ F. Picazo, Seattle, WA 3:03 COPD Exacerbations in Patients With Type 2 Diabetes on Glucagon-like Peptide-1 Receptor Agonists/ D. Foer, Boston, MA 3:15 COPD Exacerbations, Resource Use, and Costs Among COPD Patients With Eosinophil Count £ 300 Cells/µL Who Initiate Therapy With Tiotropium/olodaterol or Fluticasone Furoate/Umeclidinium/Vilanterol/ B. Clark, Ridgefield, CT 3:27 Factors Associated With Home Oxygen Reassessment After an Inpatient COPD Exacerbation/ K. Duan, Seattle, WA 3:39 Comparing Alignment of Provider- and Patient-reported Treatment Regimens With Clinical Guidelines in Chronic Obstructive Pulmonary Disease (COPD)/ M.A. Case, Baltimore, MD 3:51 Reducing Diagnostic Error to Improve Patient Safety (REDEFINE) in COPD and Asthma Study: A Cluster Randomized Comparative Effectiveness Trial/ E. Pacheco, Chicago, IL 4:03 A Web-based Physical Activity Intervention Prevents Decline in Exercise Self-regulatory Efficacy Across 3 Months in Persons With Chronic Obstructive Respiratory Disease (COPD)/ P. Bamonti, Boston, MA

exposures remain incompletely understood. This symposium will highlight recent advances in our understanding of the pathophysiological mechanisms by which these exposures damage the developing lung, the epidemiology of these early life exposures as well as highlight needed areas of research to advance treatment and prevention of these prevalent diseases. Chairing: G. Downey, MD, FRCP(C), ATSF, Denver, CO The Children Are Not OK: Reframing Our Approach to Lung Health and Lung Disease M. Han, MD, MS, ATSF, Ann Arbor, MI Tough Transitions: Sickle Cell Lung Disease Through the Ages B. Kopp, MD, MPH, ATSF, Atlanta, GA Perinatal Pulmonary Vascular Insults: How Prematurity Primes the Pump for Pulmonary Hypertension K. Goss, MD, Dallas, TX Childhood Interstitial Lung Disease: Coming of Age L. Young, MD, ATSF, Philadelphia, PA 2:27 2:42 2:57 E. Forno, MD, MPH, ATSF, Pittsburgh, PA B. Kopp, MD, MPH, ATSF, Atlanta, GA 2:15

3:12

The Changing Face of Cystic Fibrosis (CF) J. Taylor-Cousar, MD, MSc, ATSF, Denver, CO

3:27

Implications of Early Life Environmental Exposures to Adult Obstructive Lung Disease E. Forno, MD, MPH, ATSF, Pittsburgh, PA

3:42

Summary and Discussion G. Downey, MD, FRCP(C), ATSF, Denver, CO

BEHAVIORAL • CLINICAL MINI SYMPOSIUM

BASIC • CLINICAL MINI SYMPOSIUM

C93

DISPARITIES, TREATMENTS, AND OUTCOMES IN COPD

C94

CLINICAL AND TRANSLATIONAL STUDIES IN SEPSIS

2:15 p.m. - 4:15 p.m.

Walter E. Washington Convention Center Room 146 A-C (Street Level)

2:15 p.m. - 4:15 p.m.

Marriott Marquis Downtown Independence Ballroom Salons A-D (Level M4)

Chairing: L.C. Feemster, MSc, MD, Seattle, WA L.J. Harper, MD, MSCR, Cleveland, OH T.M. Parekh, DO, Austin, TX Oral Presentations: 2:15 Barriers to Cardiovascular Disease Prevention Among Black Individuals With Chronic Obstructive Pulmonary Disease/ M.L. Murphy, Brooklyn, NY 2:27 Association Between County-Level Social Vulnerability and Incident Chronic Obstructive Pulmonary Disease Among U.S. Veterans/ S. Hayes, Seattle, WA

Chairing: D. Maslove, MD, MS, FRCPC, Kingston, Canada J.D. Casey, MD, MSCR, Nashville, TN T.S. Meyhoff, MD, Copenhagen, Denmark Oral Presentations: 2:15 The Association Between Time-to-Antibiotics and Mortality in Sepsis Is Sensitive to Four Common Biases in Observational Studies/ T.R. Pak, Boston, MA 2:27 The Effect of Fluid Resuscitation Strategy on Risk for Renal Replacement Therapy Differs Based on Presence of Acute Kidney Injury in the CLOVERS Trial/ A. Khader, Seattle, WA

ATS 2023 • Washington, DC